Other targeted therapies include CBF-AML with KIT mutations and multikinase inhibitors such as midostaurin and dasatinib, which have shown promise when added to standard induction and consolidation therapies [16,17]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.